By: Benzinga
UPDATE: Bank of America Raises PO to $99 on Amgen After Omontys Recall
In a report published Monday, Bank of America reiterated a Neutral rating on Amgen (NASDAQ: AMGN ), and raised its price objective from $97 to $99. Bank of America wrote, "This weekend, AFFY/Takeda announced they were recalling all lots of their erythropoesis stimulating agent (ESA) Omontys from the market due
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here